CORDENPHARMA COLORADO (US)

Core Capabilities

  • >> Development & manufacturing of advanced intermediates & chemically synthesized APIs
  • >> Focus on synthetic peptides, highly potent cytotoxic and non-cytotoxic APIs
  • >> Large-scale peptide production
  • >> Manufacture of high volume small molecule APIs
  • >> Green manufacturing (green solvent, recycling concept for upstream & downstream solvent for peptides)

COMPLIANCE

  • >> Good inspection history with the FDA, last inspection 2016 with no observations
  • >> No violations on any DEA Inspections
  • >> No violations on RCRA inspections - 2002, 2008, 2012
  • >> No violations on OSHA Inspection - 2003
  • >> No violations on EPA / CDPHE Yearly air inspections > 2003 - 2013
  • >> No violations on Colorado Board of Pharmacy inspections > 2008 - 2013

SHE Regulatory Inspections 2017

  • >> State of Colorado Air Permit Inspection (Federal Title V Permit): No findings
  • >> City of Boulder Industrial Pretreatment Inspection (Waste Water): No findings
  • >> Boulder County (Ozone Depleting Substances): No findings
  • >> Boulder Fire Department: Two minor violations, Corrected

CordenPharma Colorado Environmental Programs Status Report

VIDEO

CordenPharma Colorado >> Watch Video

View this 2017 CordenPharma Colorado video featuring peptide, highly potent API development and manufacturing capabilities.

Facility Legacy

CordenPharma Colorado is a world leader in the development and manufacturing of chemically synthesized peptide APIs. Starting as a technology-based contract manufacturing business in 1946, it has contributed important technical advances to API manufacturing, most recently in the fields of highly active compounds and peptide synthesis. The facility is registered globally for producing four APIs and several intermediates. In addition, it has supplied clinical trials in a large number of small molecule and peptide projects, and developed second generation processes for high volume small molecules.

As a former facility of Roche, CordenPharma Colorado brings expertise in peptide and small molecule manufacturing which has been realized through significant investments in advanced chemical process equipment and state-of-the-art environmental facilities and infrastructure.

HISTORY

  • >> 1946 – 1965: Arapahoe Chemicals founded in Boulder with a focus on producing fine organic chemicals
  • >> 1965 – 1994: Acquired by Syntex Corporation, a company founded in Mexico City with a focus on oral contraceptives. Boulder production focused on Naprosyn® and highly active compounds
  • >> 1994 – 2011: Acquired by Roche, a global healthcare company based in Basel, Switzerland. Boulder production focused on peptides, highly active compounds and complex small molecules
  • >> 2011: Acquired by ICIG to become CordenPharma Colorado
 

Managing Director

Brian McCudden

Corden Pharma Colorado

2075 55th Street
Boulder, Colorado 80301

Phone: +1 (303) 442 1926
Fax: +1 (303) 938 6413

Email Human Resources